Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
CAPS Rating:
The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
RSS Headlines
Fool UK
Recs
stock picks with the potential of being doublers to multibaggers, yet risky, very risky and can go nearly to 0. hated by CAPs, but they have atleast 1 CAPs allstar that I like that has greenthumbed this one. These things have been beaten, and if 2 of 6 of em double, and another 2 don't even move, well it makes up if the last 2 go to zero n basically tank.
DMAN, FSLR, IDRA, ARQL, OSIR, MDVN